Release of a Water-Soluble Drug from a Wax Matrix Timed-Release Tablet

Goodhart, Frank W.; McCoy, Robert H.; Ninger, Fred C.

doi:10.1002/jps.2600631117

Cited by 41 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model that best fitted the release data was evaluated by correlation coefficient (R values between 0.96 and 0.98), with slope values less than 0.5, indicating that drug release mechanism from the selected tablets was diffusion controlled. This finding was in accordance with other reported works (Goodhart et al, 1974;Peterlin, 1980;Reza et al, 2002).…”

Section: Resultssupporting

confidence: 94%

Design and release characteristics of sustained release tablet containing metformin HCl

Basak¹,

Kumar²,

Ramalingam³

2008

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 94%

Design and release characteristics of sustained release tablet containing metformin HCl

Basak¹,

Kumar²,

Ramalingam³

2008

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

show abstract

“…Recently, lipids are considered as alternative to polymers in the design of sustained drug delivery systems [16] due to their chemical inertness [17], cost-effectiveness, regulatory acceptance, and above all flexibility to achieve the desired drug release profile [18]. Wide arrays of wax-lipid based hydrophobic materials are available for sustaining drug action as Compritol® 888 ATO (glyceryl behenate) [19][20][21], Precirol® ATO 5 (glyceryl palmito-stearate) [22][23][24], stearic acid [23][24][25], and tristearin [26].…”

Section: Introductionmentioning

confidence: 99%

Formulation and In Vitro and In Vivo Evaluation of Lipid-Based Terbutaline Sulphate Bi-layer Tablets for Once-Daily Administration

et al. 2015

View full text Add to dashboard Cite

Abstract. The objective of this study was to prepare and evaluate terbutaline sulphate (TBS) bi-layer tablets for once-daily administration. The bi-layer tablets consisted of an immediate-release layer and a sustained-release layer containing 5 and 10 mg TBS, respectively. The sustained-release layer was developed by using Compritol®888 ATO, Precirol® ATO 5, stearic acid, and tristearin, separately, as slowly eroding lipid matrices. A full 4×2 2 factorial design was employed for optimization of the sustainedrelease layer and to explore the effect of lipid type (X 1 ), drug-lipid ratio (X 2 ), and filler type (X 3 ) on the percentage drug released at 8, 12, and 24 h (Y 1 , Y 2 , and Y 3 ) as dependent variables. Sixteen TBS sustained-release matrices (F1-F16) were prepared by melt solid dispersion method. None of the prepared matrices achieved the targeted release profile. However, F2 that showed a relatively promising drug release was subjected to trial and error optimization for the filler composition to develop two optimized matrices (F17 and F18). F18 which consisted of drug-Compritol®888 ATO at ratio (1:6 w/w) and Avicel PH 101/dibasic calcium phosphate mixture of 2:1 (w/w) was selected as sustained-release layer. TBS bilayer tablets were evaluated for their physical properties, in vitro drug release, effect of storage on drug content, and in vivo performance in rabbits. The bi-layer tablets showed acceptable physical properties and release characteristics. In vivo absorption in rabbits revealed initial high TBS plasma levels followed by sustained levels over 24 h compared to immediate-release tablets.

show abstract

“…These systems release drug in continuous manner by dissolution-controlled and diffusion-controlled mechanisms. [3][4][5][6] One of the least complicated approaches to the manufacture of sustained release dosage forms involves the direct compression of blend of drug, retardant material and additives to formulate a tablet in which the drug is embedded in a matrix of the retardant. [7][8][9] Hydrophilic polymers are widely used in the formulation of modified release oral dosage forms.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Ketoprofen Trilayered Matrix Tablet

Navaneetha¹,

Saritha²,

Reddy³

et al. 2017

Int. Res. J. Pharm.

View full text Add to dashboard Cite

The aim of the present work is to design and evaluate the controlled release Ketoprofentrilayered matrix tablets, to release the drug for prolonged period of time, which follows zero order kinetics by maintaining a constant drug level in the plasma. Formulations were prepared by using different ratios of polymers like Hydroxy propyl methyl cellulose (K100 &6 cps) and Ethyl cellulose. The FTIR analysis assured compatibility of drug and excipients. Trilayered tablets containing middle drug core layer and either side of core layer, a barrier polymer layers present, prepared by wet granulation method. After formulation development, the trilayered tablets were evaluated for their appearance, hardness, friability, weight variation, disintegration time, assay, in-vitro drug release and stability studies. Core granuleswhich have shown the desired drug release were selected to prepare the trilayered matrix tablets. Based on the evaluation studies FF8 formulation was optimized. FF8 showed in-vitro drug release of 95.8% for 24h which is shown to have better release than marketed preparation hence considered as most promising preparation. Drug release values of optimized formulation (FF8) were subjected to mathematical kinetic modeling, and the correlation coefficient (R 2 ) values drug release follows zero-order (0.994) kinetics and mechanism of dug release is by KorresmayerPeppas model (0.993). FF8 formulation subjected for accelerated stability study for 3 months and the formulation was found to be stable during the study period.

show abstract

Release of a Water-Soluble Drug from a Wax Matrix Timed-Release Tablet

Cited by 41 publications

References 6 publications

Design and release characteristics of sustained release tablet containing metformin HCl

Design and release characteristics of sustained release tablet containing metformin HCl

Formulation and In Vitro and In Vivo Evaluation of Lipid-Based Terbutaline Sulphate Bi-layer Tablets for Once-Daily Administration

Formulation and Evaluation of Ketoprofen Trilayered Matrix Tablet

Contact Info

Product

Resources

About